Global Market Comments
September 25, 2020
Fiat Lux
Featured Trade:
(HERE’S MY NEXT CHIP TEN BAGGER),
(AMD), (INTC), (NVDA), (MU)
I am often asked which semiconductor company to buy. After all, this is not just the high beta play for the stock market as a whole, but the entire economy as well.
When times are good, consumers can’t get enough chips to stockpile. When they are bad, they are used as landfill. Semiconductors are the economy on a bungee cord.
For the past five years, the answer was always the same: top-end graphics card maker Nvidia (NVDA).
It was a great call. Since my initial recommendation in 2015, the stock has soared by tenfold, one of several ten-baggers I have been able to rake in during recent years.
Now it’s time to call the next ten-bagger.
That’s easy enough: Advanced Micro Devices (AMD).
(AMD) is an American multinational semiconductor company based in Santa Clara, California that develops computer processors and related technologies for business and consumer markets.
While it initially manufactured its own processors, the company later outsourced all its manufacturing, a practice known as going fabless, after GlobalFoundries was spun off in 2009. Chip foundry Taiwan Semiconductor Manufacturing (TSM) currently produces (AMD)'s chips.
AMD's main products include microprocessors, motherboard chipsets, embedded processors, and graphics processors for servers, workstations, personal computers, and embedded system applications.
In 2019, (AMD) brought in $6.48 billion in revenues, $631 million in operating revenue, and $341 million in net profits. It pays no dividend. For the current quarter, (AMD) expects revenue to rise an eye-popping 42% year over year to $2.55 billion.
The company was considered a lagging “also ran” for years, the poor cousin of Intel (INTC), Micron Technology (MU), and powerhouse Nvidia (NVDA).
Then Lisa Hsu took over in 2014. It has been straight up ever since. She immediately launched into a new generation of faster and more efficient chips, such as the Ryzen PC processors and Epyc server chips in 2017.
(AMD) now expects to ship its first revolutionary 7-nanometer processors in late 2022 or early 2023. Next to follow will be once unimaginable 3-nanometer processors. Now we are trying to get single electrons to go through gates.
AMD is also working with Hewlett Packard Enterprise (HPE) and nearby Lawrence Livermore National Laboratory on the El Capitan supercomputer for the U.S. Department of Energy. That gives the company another big advantage in developing new chip technologies.
As a result of (AMD)’s Herculean efforts, Intel was left behind in the dust, as its share price amply demonstrates.
Despite its recent ballistic growth (AMD) is still the smaller of the major chip companies. Its market capitalization stands at only $90 billion, compared to $209 billion for fading (INTC) and a monster $308 billion for (NVDA). Yet (AMD) boasts a higher growth rate.
If a global economic recovery ensues in 2021, (AMD) will be your play. As the move online vastly accelerates thanks to the pandemic, a global chip shortage is in the cards. Earnings, multiples, and share prices should all go up. The recent economic data from China shows that we are certainly headed in that direction.
Use this major selloff to stick your toe into (AMD).
To learn more about Advanced Micro Devices, please visit their website by clicking here.
While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more
Mad Hedge Technology Letter
September 25, 2020
Fiat Lux
Featured Trade:
(CASHLESS PAYMENTS ARE HERE TO STAY)
(SQ)
Cashless payments have gained a major foothold into consumer’s lives all brought about by the pandemic, according to a new consumer survey.
This transformational trend is just another reason traders should look at Fintech firm Square (SQ) which has been one of my favorite tech stocks for the past 2 years.
The never-ending pandemic has accelerated the trend toward cashless transactions and the digit economy.
Conversely, the non-cashless society has taken the brunt of the pain in the form of job losses and the jobless rates remain stubbornly high in the Northeast and West trending above 10% in 10 states in the U.S. last month.
It’s clear which area of the economy to invest in and that’s digital payments.
Before the pandemic, in February 2020, 5.4% of Square sellers in the US were cashless, which Square defines as any business accepting more than 95% of their sales by in-person credit or debit card payments, online payments, or contactless payments.
Moving to April, that number soared to 23.2% and by August, when many stay-at-home restrictions were lifted, it was 30%.
To highlight the trend away from a hard currency society, for payments transacted by Square sellers, the share of cash transactions dropped from 37% in February to 33% in April at the height of the lockdown.
Square delivered an analysis indicating it would take over four years to achieve this oversized cashless drop.
That is the underlying story of the pandemic – multiple years of digital transformation and acceleration scrunched into 7 months.
Not only have the secular trends strengthened tech’s fundamentals, but the employees themselves have collaborated to deliver new products such as On-Demand Pay which will allow Square merchant employees to take a cash advance of up to $200 with no fee. The second service is Instant Payments which allows sellers to fund their payroll from their Square Seller account, speeding up the transaction.
Both services take advantage of the increasing number of consumers using Cash App, delivering wider access to cash for both employers and employees. The synergies between Square's consumer and seller ecosystem is a significant competitive advantage for the company that should drive continued adoption of its products and services.
Scaling the individual ecosystem, cross-selling services within each ecosystem, and finally connecting the ecosystem has been an effective three-prong strategy for Square’s management.
These are services that minimize business risk and an example of how it can disrupt the old way of handling something like payroll. As the two ecosystems grow, Square may find other areas where it can create value between them.
The new products will improve adoption for Payroll among merchants while boosting Cash App adoption and the direct-deposit feature in particular.
Both services will boost increased balances in seller and Cash App accounts. That should increase the appeal of other Square services like the Square Card or Cash Card. It could also lead to more Cash App users investing or sending cash to friends.
It would make sense that greater balances in seller accounts would produce similar results on the seller side. And as Square merchants use more than one service from the company, Square can start offering even better deals to sellers.
In the future, other products that could be rolled out include avenues like loyalty programs, lending products, or other ways to facilitate commerce. Square is just getting started, but the fintech company's new Payroll products show the potential to create significant change in the small business financial services industry and seize market share.
Contrast the bustling activity happening in the fintech space with brick and mortar stores and the difference couldn’t be starker.
The follow-through has been vivid with Square’s shares lurching higher by 150%.
Not only do Square’s engineers work together to create more revenue-building products at scale, but Square is feasting from a once in a generation pivot to mobile digital payments.
Square’s formula has been a recipe for success proving that the road to Damascus is shorter than it seems.
I am highly bullish Square.
“You don't have to start from scratch to do something interesting.” – Said CEO of Twitter and Square Jack Dorsey
Today, I would like to make a suggestion on a stock we have traded in the past.
The stock is Harley Davidson, Inc. (HOG).
HOG is oversold and is trading relatively flat today, as I write this.
It is oversold by virtue of the fact that it is trading right at its lower band on the 60 minute chart.
I would like to suggest a weekly covered call on the stock and use next week's expiration, which is October 2nd.
HOG is trading right at $23.25 as I write this.
Buy HOG at the market and then execute the sale of this call.
Sell to Open (1) October 2nd - $24.00 Call for every 100 shares you own.
You should be able to sell them for $.45 per every option.
If the calls are assigned next Friday, the return will be about 5.2% for seven days.
Based on the nominal portfolio, limit the buy in to 300 shares, which is 7% of the portfolio.
While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more
Mad Hedge Biotech & Healthcare Letter
September 24, 2020
Fiat Lux
(PLAY YOUR CARDS RIGHT WITH MODERNA)
(MRNA), (PFE), (AZN), (BNTX), (JNJ), (MRK), (VRTX), (CRSP)
The COVID-19 race is entering the home stretch, and it could only be a matter weeks before the world finds out which among the leading vaccine candidates will work.
For months, Moderna (MRNA) has been dubbed as the leader of the pack, with the company’s shares reaping the rewards thanks to this year’s wild growth and promising clinical results.
Now, it looks like Moderna is on the verge of officially claiming the crown as promising reports surfaced from its late-stage clinical trials.
If the Moderna’s COVID-19 vaccine candidate, called mRNA-1273, is proven to be at least 70% effective, the company will immediately ask for an emergency authorization to use it on high-risk patients.
Like Pfizer (PFE), Moderna is also expecting results to come as early as October. With potential delays in the trials, the company thinks the data would be released by November at the latest.
Moderna is also looking into building footprints outside the United States.
Part of its efforts to expand its potential market reach for mRNA-1273, Moderna opened a commercial hub – its first ever – in Switzerland, where it has already been collaborating with Swiss drug manufacturer Lonza (SWX: LONN).
This is a good move for Moderna.
After all, Europe presents a substantial market for the COVID-19 vaccine. For context, the European Union has over 446 million people while the US only has 328 million.
To date, Moderna has agreed to supply 100 million doses of its COVID-19 vaccine to the US government for up to $1.525 billion. The contract also provides for an optional additional 400 million doses, depending on mRNA-1273’s performance in the trials.
Meanwhile, Moderna already secured a deal with the Swiss federal government to deliver 4.5 million of mRNA-1273.
While it has yet to announce a similar deal with the rest of the EU, the company is reported to be in the advanced stages of its negotiations with other member countries, where it is estimated to provide an additional 160 million doses.
Overall, the global manufacturing projection for Moderna falls somewhere between 500 million and 1 billion doses starting in 2021.
Looking at the agreements, we can conservatively say that mRNA-1273 could rake in $12.4 billion in sales for Moderna by 2022.
Despite the current payment plans implying that each dose of Moderna’s vaccine would only cost $15.25, the company already received government funding of roughly $2.5 billion.
Taking those expenses into account, the actual value would be somewhere between $25 and $30 per dose.
In comparison, Pfizer’s vaccine candidate with BioNTech (BNTX) is estimated to cost less than $19.50 per dose while Johnson & Johnson (JNJ) announced that it will offer its vaccine at $10 per dose.
Meanwhile, AstraZeneca’s (AZN) candidate with Oxford University is expected to be even cheaper at $2.96 to $4 per dose.
With its COVID-19 vaccine rivals offering decidedly cheaper options, Moderna will need to leverage its first-mover advantage if it hopes to fight for a decent market share.
Outside COVID-19 vaccine efforts, Moderna has a rich pipeline, with 23 candidates distributed over 22 programs and 6 modalities.
Aside from the urgent need to offer a vaccine to the world, there is another reason why Moderna is focusing on the COVID-19 program right now.
If proven successful, the program can be used to validate another experimental vaccine, called mRNA-1647, which targets congenital cytomegalovirus infection.
Although CMV is identified as one of the leading causes of birth defects in the US, there remains no approved vaccine for it.
However, there is a catch.
Moderna will not be able to reap the full benefits of the CMV vaccine.
In fact, it will only be able to receive 50% of its profits if it becomes successful since mRNA-4157 is being developed alongside Merck (MRK).
The idea is for the drug to boost the oncology sector of Merck, with the goal of finding another blockbuster like the melanoma drug Keytruda.
As impressive as the CMV vaccine is as a product to launch in the market, there is a huge possibility that Moderna would not necessarily benefit from a large windfall because of it.
Aside from Merck, Moderna is also working with another biopharmaceutical giant and competitor in the COVID-19 vaccine race: Vertex (VRTX).
Moderna and the Massachusetts-based giant are collaborating to develop a treatment for cystic fibrosis, a niche that Vertex has dominated for years.
This is actually their second collaboration, but this project seems a tad more ambitious than the earlier one: Moderna and Vertex are working to develop a one-time treatment for cystic fibrosis using mRNA technology.
Basically, the two companies want to use gene-editing techniques to modify a patient’s DNA and correct the cells that cause cystic fibrosis.
The collaboration will span 3 years, with Vertex paying Moderna $75 million upfront. The smaller biotechnology company is also eligible for an additional $380 million in milestone payments plus royalties.
Notably, this is not the first cystic fibrosis treatment collaboration that Vertex formed with gene-editing companies.
Earlier this year, the company also secured a license option with CRISPR Therapeutics (CRSP) to work on practically the same thing.
Clearly, Vertex is hedging its bets on two potential options with this second partnership with Moderna.
Thanks to its trailblazing COVID-19 vaccine candidate, Moderna has become one of the most sought-after stocks of 2020, with its year-to-date growth reaching a stunning 360% last July.
Despite the temptation to bet big on Moderna stocks, bear in mind that early leaders like this biotechnology company will be facing incredible pressure from pharmaceutical titans like Pfizer, Johnson & Johnson, and AstraZeneca – all of which have the capacity to meet the manufacturing and distribution demands across the globe.
At best, a company with Moderna’s size would probably receive a slice of the market in the early days.
At worst, it might struggle to keep a foothold as stronger and larger competitors flood the market with cheaper but equally effective alternatives.
Nonetheless, this is not to say that you should completely avoid smaller biotechnology companies just because they are too small to compete with the larger fish.
Rather, I think it would simply be prudent to invest based on each player’s proven ability and outlined plans to meet the demand at a mass scale.
Doing so would guarantee that you not only limit your risks but also allow you to reap the rewards of successful vaccine deployment. If you play your cards right, then you might even get a handful of different COVID-19 vaccine winners in your back pocket.
